As originally reported on April 25, 2013 (DePuy’s Knee Implants Failing), patients receiving DePuy’s antibiotic-containing bone cement may be at risk of failure and loosening of their knee implants. Burg Simpson has filed a complaint in the Southern District of Ohio against DePuy Orthpaedics, Inc., and Johnson & Johnson, the parent of DePuy, on behalf of a patient who required a premature revision of her knee implant after the DePuy Gentamicin containing bone cement in her original device failed to adequately adhere to the device and bone. FDA adverse event reports indicate that the failure of DePuy’s Gentamicin (antibiotic) bone cement has resulted in loosening of joint replacement devices. Failure of the bone cement and resulting revision surgery may lead to damage to the bone and surrounding tissue.
Free Case Evaluation
Please fill out the case evaluation form below, or call Burg Simpson directly at 513-852-5600 today.
Subscribe today and get the latest Burg Simpson related updates via email: